Cargando…
Fabry Disease Therapy: State-of-the-Art and Current Challenges
Fabry disease (FD) is a lysosomal storage disorder caused by mutations of the GLA gene that lead to a deficiency of the enzymatic activity of α-galactosidase A. Available therapies for FD include enzyme replacement therapy (ERT) (agalsidase alfa and agalsidase beta) and the chaperone migalastat. Des...
Autores principales: | Azevedo, Olga, Gago, Miguel Fernandes, Miltenberger-Miltenyi, Gabriel, Sousa, Nuno, Cunha, Damião |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794923/ https://www.ncbi.nlm.nih.gov/pubmed/33379210 http://dx.doi.org/10.3390/ijms22010206 |
Ejemplares similares
-
Fabry Disease and the Heart: A Comprehensive Review
por: Azevedo, Olga, et al.
Publicado: (2021) -
Parkinson’s Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees
por: Gago, Miguel Fernandes, et al.
Publicado: (2020) -
Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation
por: Azevedo, Olga, et al.
Publicado: (2020) -
Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy
por: Aguiar, Patrício, et al.
Publicado: (2018) -
Rare Association of two Genetic Causes of Sudden Death in a Young
Survivor
por: Brito, Dulce, et al.
Publicado: (2017)